It was lovely to speak with Jacqueline Barrientos of @MountSinaiMiami at #ASH25 to hear about the disparities in access to frontline therapies in patients with CLL in the United States.🩸

Make sure to watch the interview here:
👉 👈

#CLLsm #Leusm

Drivers of racial and ethnic disparities in access to frontline CLL therapy in the US

Jacqueline Barrientos, MD, MS, Mount Sinai Medical Center, Miami Beach, FL, discusses the disparities in access to f...

ow.ly

To hear an overview of the ongoing PhII ALPHA3 study evaluating first-line consolidation with cema-cel in patients with LBCL who have detectable MRD by ctDNA after standard frontline treatment, watch our recent interview with John Burke by clicking here:

🎥 ➡️

INCA033989, a novel mutant CALR-specific monoclonal antibody, was a hot topic in the field of MPNs at #ASH25, with promising early results in both #EssentialThrombocythemia & #Myelofibrosis.🩸

Hear more from @harrisoncn1 of @GSTTnhs:
🎥 👉

#MPNsm #HemOnc

Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF

Claire Harrison, MD, FRCP, FRCPath, Guy's and St Thomas' NHS Foundation Trust, London, UK, discusses the safety and ...

ow.ly

In an interview from #ASH25, @akshatdoctor (@LLUMedSchool) discusses real-world experience with the anti-tissue factor pathway inhibitor marstacimab in severe & non-severe #hemophilia, highlighting its potential to revolutionize treatment for patients.

Click to watch: 🎥